CARDOZA GEORGE sold $13K of SOPH
CARDOZA GEORGE (Chief Financial Officer) sold 1,592 shares of SOPHiA GENETICS SA (SOPH) at $8.10 on 2026-10-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is small and pre‑arranged, so it is unlikely to move the stock significantly.
Market read
Routine insider sale with limited trading relevance.
What to watch
The sale reduces the CFO's stake to 306,726 shares, which still represents a sizable holding; the market may view the remaining stake as a sign of confidence.
Background
SEC Form 4 filings provide the first public disclosure of insider transactions.
Ticker impact
CFO Cardoza George sold 1,592 SOPH shares for $12,897 via a 10b5‑1 plan on 2026‑10‑05.
likely modest pressure as the market prices in the insider sell.
The transaction size ($13K) is small relative to total holdings (306,726 shares) and was pre‑arranged, so the impact is limited.
Market effects
Minimal effect on the broader biotech/genomics sector.
No notable regional impact.
Limited to SOPH investors.
Counterpoint
Some investors may view any insider sell as a red flag, but the pre‑arranged nature suggests no new negative information.
Key entities
- companySOPHiA GENETICS SA
Swiss biotech firm listed on NASDAQ under SOPH.
- personCardoza George
Chief Financial Officer of SOPHiA GENETICS.
